Gujarat Kidney and Super Speciality Ltd FY26 Results Show Strong Growth

Gujarat Kidney and Super Speciality Ltd has announced its financial results for the year ended March 31, 2026, showcasing a significant surge in both revenue and profitability on a consolidated basis.

Consolidated revenue from operations reached ₹82.01 crore, marking a substantial increase of 103.8% from ₹40.24 crore in the previous fiscal year. Profit after tax (PAT) also saw robust growth, rising by 77% to ₹16.81 crore in FY26 compared to ₹9.50 crore in FY25.

On a standalone basis, revenue from operations grew to ₹40.10 crore for the year ended March 31, 2026, up from ₹35.17 crore in FY25. Standalone PAT improved to ₹9.90 crore from ₹9.11 crore in the prior year.

Reader Takeaway: Strong revenue and profit growth driven by consolidated operations; IPO object variation needs investor scrutiny.

What just happened

The company reported its financial results for the fiscal year 2025-26. Key highlights include a more than doubling of consolidated revenue and a significant increase in consolidated profit after tax. The company also plans to seek shareholder approval via a postal ballot for a variation in the objects of its Initial Public Offering (IPO).

Why this matters

The impressive growth in revenue and profits indicates strong business performance and market reception. The proposed variation in IPO objects is crucial for investors as it signals a potential change in how the company intends to utilize its raised capital, which could impact future strategic direction.

The backstory

Gujarat Kidney and Super Speciality Ltd operates in the healthcare sector, focusing on kidney-related and other super speciality medical services. The company previously conducted an IPO, and this filing relates to the utilization of those funds.

What changes now

Financially, the company demonstrates a strong upward trajectory. Operationally, the upcoming postal ballot on the IPO objects variation will be a key event for shareholders to monitor. The Board has also deferred the decision on CEO appointment, leaving that leadership role open for now.

Risks to watch

A primary risk for investors lies in the proposed variation of IPO objects. The market will be watching closely to understand the rationale and impact of this change on the company's strategic plans and capital allocation. The deferral of the CEO appointment might also be a point of concern if it signals internal indecision or challenges.

Peer comparison

Detailed peer comparison data was not provided in the filing. However, strong revenue growth in the healthcare sector is generally viewed positively, especially for specialized services like those offered by Gujarat Kidney and Super Speciality Ltd.

Context metrics (time-bound)

• Consolidated Revenue FY26: ₹82.01 crore (+103.8% YoY)
• Consolidated PAT FY26: ₹16.81 crore (+77% YoY)
• Standalone Revenue FY26: ₹40.10 crore
• Standalone PAT FY26: ₹9.90 crore

What to track next

Investors should closely track the outcome of the postal ballot regarding the variation in IPO objects. Additionally, the eventual appointment of a CEO will be an important development for the company's leadership structure and future strategy.